Cargando…

A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice

For prevention of HIV infection many currently licensed anti-HIV drugs and new ones in the pipeline show potential as topically applied microbicides. While macaque models have been the gold standard for in vivo microbicide testing, they are expensive and sufficient numbers are not available. Therefo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neff, C. Preston, Kurisu, Theresa, Ndolo, Thomas, Fox, Kami, Akkina, Ramesh
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105981/ https://www.ncbi.nlm.nih.gov/pubmed/21673796 http://dx.doi.org/10.1371/journal.pone.0020209

Ejemplares similares

Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model
por: Neff, C. Preston, et al.
Publicado: (2010)

HIV-1 infection and CD4 T cell depletion in the humanized Rag2(-/-)γc(-/- )(RAG-hu) mouse model
por: Berges, Bradford K, et al.
Publicado: (2006)

Humanized Rag1(−/−)γc(−/−) Mice Support Multilineage Hematopoiesis and Are Susceptible to HIV-1 Infection via Systemic and Vaginal Routes
por: Akkina, Ramesh, et al.
Publicado: (2011)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

Vaginal deployment and tenofovir delivery by microbicide gels
por: Gao, Y., et al.
Publicado: (2015)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
por: Ochoa-Callejero, Laura, et al.
Publicado: (2013)

Enzyme Responsive Vaginal Microbicide Gels Containing Maraviroc and Tenofovir Microspheres Designed for Acid Phosphatase-Triggered Release for Pre-Exposure Prophylaxis of HIV-1: A Comparative Analysis of a Bigel and Thermosensitive Gel
por: Ekama, Sabdat Ozichu, et al.
Publicado: (2021)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2022)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure
por: Ishihara, Yasuhiro, et al.
Publicado: (2022)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
por: Ferrero, Maximiliano Ruben, et al.
Publicado: (2021)

Vaginal rings for delivery of HIV microbicides
por: Malcolm, R Karl, et al.
Publicado: (2012)

Acceptability of Carraguard Vaginal Microbicide Gel among HIV-Infected Women in Chiang Rai, Thailand
por: Whitehead, Sara J., et al.
Publicado: (2011)

In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection
por: Gramegna, Pasqua, et al.
Publicado: (2011)

SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses
por: Tsibris, Athe M. N., et al.
Publicado: (2011)

HIV-1 infection and CD4 T cell depletion in humanized Rag2-/-yc-/- mice
por: Berges, Bradford, et al.
Publicado: (2006)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

The Development of Vaginal Microbicides for the Prevention of HIV Transmission
por: Weber, Jonathan, et al.
Publicado: (2005)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation
por: Merino, José Joaquín, et al.
Publicado: (2020)

Measuring Dilution of Microbicide Gels with Optical Imaging
por: Drake, Tyler K., et al.
Publicado: (2013)

A Multi-Compartment, Single and Multiple Dose Pharmacokinetic Study of the Vaginal Candidate Microbicide 1% Tenofovir Gel
por: Schwartz, Jill L., et al.
Publicado: (2011)

Potential Use of Antimicrobial Peptides as Vaginal Spermicides/Microbicides
por: Tanphaichitr, Nongnuj, et al.
Publicado: (2016)

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability
por: Casagrande, Naike, et al.
Publicado: (2021)

Microbicides Development Programme: Engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania
por: Vallely, Andrew, et al.
Publicado: (2009)

Formulation of the Microbicide INP0341 for In Vivo Protection against a Vaginal Challenge by Chlamydia trachomatis
por: Pedersen, Christian, et al.
Publicado: (2014)

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
por: Roche, Michael, et al.
Publicado: (2013)

Efficacy dilution in randomized placebo-controlled vaginal microbicide trials
por: Mâsse, Benoît R, et al.
Publicado: (2009)

Twice-Daily Application of HIV Microbicides Alters the Vaginal Microbiota
por: Ravel, Jacques, et al.
Publicado: (2012)

Do vaginal microbicides reduce the risk of HIV acquisition in women?
por: Obiero, Jael Apondi, et al.
Publicado: (2022)

HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector
por: Anderson, Joseph, et al.
Publicado: (2005)

Stable gene transfer of CCR5 and CXCR4 siRNAs by sleeping beauty transposon system to confer HIV-1 resistance
por: Tamhane, Mayur, et al.
Publicado: (2008)

Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc
por: Savkovic, Borislav, et al.
Publicado: (2012)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics
por: Karris, Maile Y., et al.
Publicado: (2016)

CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection
por: Anderson, Joseph, et al.
Publicado: (2005)

Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission
por: Cone, Richard A, et al.
Publicado: (2006)

Analysis of Vaginal Microbicide Film Hydration Kinetics by Quantitative Imaging Refractometry
por: Rinehart, Matthew, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5rva576v2rrtdliikc9ovn8a6l